Yuki Ishibashi

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 560 citations · Full text

Medicine, Cardiology, Surgery +17

Fast virtual functional assessment of intermediate coronary lesions using routine angiographic data and blood flow simulation in humans: comparison with pressure wire – fractional flow reserve

Michail I. Papafaklis, Takashi Muramatsu, Yuki Ishibashi et al. · EuroIntervention · 2014 · 182 citations

Medicine, Cardiology, Computational Fluid Dynamics +16

Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study

Roberto Diletti, Takashi Muramatsu, Shimpei Nakatani et al. · European Heart Journal · 2014 · 111 citations · Full text

Medicine, Biomedical Engineering, Cardiology +17

The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial

Pannipa Suwannasom, Yohei Sotomi, Yuki Ishibashi et al. · JACC: Cardiovascular Interventions · 2016 · 94 citations

Medicine, Cardiology, Surgery +14

Physiological Pattern of Disease Assessed by Pressure-Wire Pullback Has an Influence on Fractional Flow Reserve/Instantaneous Wave-Free Ratio Discordance

Takayuki Warisawa, Christopher Cook, James P. Howard et al. · Circulation Cardiovascular Interventions · 2019 · 83 citations · Full text

Medicine, Cardiology, Physiology +16